What type of study is this?

November 23, 2025The American Journal of Drug and Alcohol Abuse

Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries

View Full Paper

Ask AI

Bookmark

Medications for opioid use disorder lower overdose risk following diagnosis, with methadone and buprenorphine providing greater protection than naltrexone.
Methadone therapy reduced overdose risk to a hazard ratio of 0.14, while buprenorphine similarly provided robust protection against medically treated overdoses.
Cohort study of 1,172,200 Medicaid enrollees used Cox proportional hazards models, highlighting urgent needs to expand equitable access to timely pharmacotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cohort study reveals methadone and buprenorphine lower overdose risk among Medicaid enrollees with opioid use disorder, highlighting racial disparities in timely treatment receipt.

Cite This Study

Treitler et al. (2025) studied this question.

synapsesocial.com/papers/69403fa32d562116f290e57c https://doi.org/10.1080/00952990.2025.2557917

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals methadone and buprenorphine lower overdose risk among Medicaid enrollees with opioid use disorder, highlighting racial disparities in timely treatment receipt.

Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries

Key Points

Discussion

Implication

Cite This Study

Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider